ALA · ASX

Arovella Therapeutics Limited (ASX:ALA)

AU$0.099

 0.004 (4.211%)
ASX:Live
24/04/2025 04:10:05 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ALA Overview

ALA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Weak

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ALA

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$112.47M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.07 - 0.21

Trade Value (12mth)

AU$54,095.00

1 week

26.92%

1 month

17.86%

YTD

-41.76%

1 year

-13.91%

All time high

14.78

Key Fundamentals

EPS 3 yr Growth

-38.80%

EBITDA Margin

%

Operating Cashflow

-$7m

Free Cash Flow Return

-92.10%

ROIC

-116.60%

Interest Coverage

-1,247.60

Quick Ratio

6.40

Other Data

Shares on Issue (Fully Dilluted)

1054m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date Announcements

24 April 25

Notification regarding unquoted securities - ALA

×

Notification regarding unquoted securities - ALA

16 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

16 April 25

Quarterly Update Webinar

×

Quarterly Update Webinar

10 April 25

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

01 April 25

Cancel - Proposed issue of securities - ALA

×

Cancel - Proposed issue of securities - ALA

01 April 25

Cancel - Proposed issue of securities - ALA

×

Cancel - Proposed issue of securities - ALA

27 March 25

Notification of cessation of securities - ALA

×

Notification of cessation of securities - ALA

26 March 25

Prospectus

×

Prospectus

26 March 25

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

26 March 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

26 March 25

Quotation of Options

×

Quotation of Options

07 March 25

S&P DJI Announces March 2025 Quarterly Rebalance

×

S&P DJI Announces March 2025 Quarterly Rebalance

05 March 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

05 March 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

05 March 25

Top 20 Holders and Range of Units for Attaching Options

×

Top 20 Holders and Range of Units for Attaching Options

03 March 25

Letter from Managing Director and CEO

×

Letter from Managing Director and CEO

03 March 25

Research Agreement with University of North Carolina

×

Research Agreement with University of North Carolina

27 February 25

Half Year Report and Appendix 4D

×

Half Year Report and Appendix 4D

26 February 25

Arovella $15m Placement to fund Phase 1

×

Arovella $15m Placement to fund Phase 1

26 February 25

Prospectus

×

Prospectus

26 February 25

Cancel - Proposed issue of securities - ALA

×

Cancel - Proposed issue of securities - ALA

26 February 25

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

26 February 25

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

26 February 25

Reinstatement to Official Quotation

×

Reinstatement to Official Quotation

10 February 25

Voluntary Suspension

×

Voluntary Suspension

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

-0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.099.
The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.21.
The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.07.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.
Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.
The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.